Drug Approval | December 28, 2021
Strides to market molnupiravir under the brand name Stripiravir
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The company will market it under the brand name Molflu
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
Flattish volume growth and subdued new launches were key factors for last month
The hospital has recently launched Radionuclide therapy
The company will collaborate with U.S.-based colleagues to help life sciences companies improve commercial effectiveness
Since its launch, the medical devices park in Sultanpur has received overwhelming response with more than 50 companies lining up to set up their manufacturing or research and development units
The campaign “Care is Just An Aster Away” was launched along with the unveiling of the new corporate logo on Burj Khalifa on 11th December
KOREA PACK and concurrent event ICPI Week (Int’l Cosmetic and Pharmaceutical Industry Week) will be held as hybrid events in 2022
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
Subscribe To Our Newsletter & Stay Updated
